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Background: Expressing several markers of migrating primordial germ cells (PGCs), the rare population of quiescent,
bone marrow (BM)-residing very small embryonic-like stem cells (VSELs) can be specified like PGCs into hematopoietic
stem/progenitor cells (HSPCs). These two properties of VSELs support the possibility of a developmental origin of HSPCs
from migrating PGCs.
Methods: To address a potential link between VSELs and germ line cells we analyzed by RT-PCR and FACS expression
of erythropoietin receptor (EpoR) on murine bone marrow- and human umbilical cord blood-derived VSELs, murine and
human teratocarcinoma cell lines and human ovarian cancer cells. A proper gating strategy and immunostaining
excluded from FACS analysis potential contamination by erythroblasts. Furthermore, the transwell chemotaxis
assays as well as adhesion and signaling studies were performed to demonstrate functionality of erythropoietin - EpoR
axes on these cells.
Results: We report here that murine and human VSELs as well as murine and human teratocarcinoma cell lines
and ovarian cancer cell lines share a functional EpoR.
Conclusions: Our data provide more evidence of a potential developmental link between germline cells, VSELs,
and HSCs and sheds more light on the developmental hierarchy of the stem cell compartment in adult tissues.
Keywords: EpoR, Germ line, Cancer development, VSELs, Ovarian cancerIntroduction
The recent hot debate over the existence of develop-
mentally primitive stem cells in bone marrow (BM)
with broad differentiation potential has been fueled by
the challenge these cells pose to the accepted hierarchy
within the stem cell compartment of hematopoietic tis-
sues [1]. Also surprising is the accumulating evidence
that hematopoietic stem cells (HSCs) are specified
from a population of migrating primordial germ cells* Correspondence: mzrata01@louisville.edu
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unless otherwise stated.(PGCs) during embryogenesis [2-4] and that stem cells
with germ cell potential reside in adult BM [5,6].
In support of this intriguing linkage, HSCs and PGCs
are highly migratory cells, and specification of the first
primitive HSCs in the yolk sac blood islands as well as
the origin of definitive HSCs in the aorta–gonado–
mesonephros (AGM) region are chronologically and
anatomically correlated with the developmental migra-
tion of PGCs in extra- and intra-embryonic tissues [7].
In addition, several papers have described the sharing of
chromosomal aberrations between germline tumors and
leukemias or lymphomas, which suggests their clonal origin
[8-10]. Furthermore, it has been demonstrated in in vitro
cultures that murine PGCs isolated from embryos, stem
cells isolated from murine testes [4], and teratocarcinomaral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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tor cells (HSPCs) [11].
Our recent work demonstrated the presence of small,
quiescent, Sca-1+Lin−CD45− stem cells in adult murine
BM and small CD133+Lin−CD45− cells in human BM
and umbilical cord blood (UCB) [12-16]. These cells,
under appropriate co-culture conditions with OP-9 stro-
mal cells, can be specified into HSPCs [17], and, based
on the presence of a primitive type of chromatin in their
nuclei as well as expression of embryonic stem cell
markers such as Oct-4 and Nanog, these small cells were
named very small embryonic-like stem cells (VSELs).
Interestingly, murine VSELs express several markers,
such as Stella, Prdm14, Fragilis, Blimp1, Nanos3, and
Dnd1, that are shared with migratory primordial germ
cells PGCs [18,19]. Based on these observations, we have
proposed a developmental link between PGCs, VSELs,
and HSCs [17,19]. We have also hypothesized that these
cells, if mutated, may give rise to certain types of malig-
nancies [20], which may reconcile the presence of these
cells in adult tissues with the more than 150-year-old
embryonic rest hypothesis of cancer development.
The erythropoietin receptor (EpoR) is well known to
be essential for production of red blood cells. Recently,
however, evidence has accumulated that it is also expressed
in non-hematopoietic tissues (e.g., some neuronal cells)
[21]. Accordingly, EpoR has also been reported to be
expressed by several types of malignant cells, including
ovarian cancer cell lines [22,23]. These findings prompted
us to evaluate the expression of EpoR on murine and hu-
man VSELs as well as murine and human germline-derived
cell lines. The presence of EpoR on VSELs and germline
cell lines provides new evidence for a developmental link
between VSELs, HSCs, and the germline and sheds more
light on the developmental hierarchy within the adult stem
cell compartment.
Materials and methods
Murine BM and human umbilical cord blood cells and
cell lines
Mononuclear cells were isolated from BM of 4–6-week-old
C57Bl/6 mice and human umbilical cord blood in agree-
ment with approval by the Animal Care and Use Commit-
tee (IACUC) and Institutional Review Board (IRB) of
the University of Louisville (Louisville, KY). All cell lines
employed in our studies (P19, NTERA2, A2780) were pur-
chased from ATCC (Manassas, VA, USA). C57Bl/6 mice
were purchased from Jackson Laboratories (Bar Harbor,
ME, USA). Clinical-grade UCB research units were shipped
from the Cleveland Cord Blood Center.
Isolation of murine VSELs
Mice were sacrificed and bone marrow was flushed from
the femur and tibia. A single-cell suspension was obtainedby agitation through the syringe. Cells were lysed in
BD lysing buffer (BD Pharmingen) for 10 min at room
temperature and washed twice in RPMI medium with
2% FBS. The cell suspension was stained for the VSEL
phenotype using antibodies: anti-CD45R/B220 (PE,
clone RA-6B2), anti-Gr-1 (PE, clone RB6-8 C5), anti-T
cell receptor αβ (PE, clone H57-5970), anti-T cell re-
ceptor ɤδ (PE, clone GL3), anti-CD11b (PE, clone M1/
70), anti-Ter119 (PE, clone TER-119), anti-CD45 (allo-
phycocyanin–Cy7, clone 30 F11) and anti-Ly-6A/E
(also known as Sca-1, PE–Cy5 or Alexa Fluor 647,
clone E13-161.7) for 30 minutes on ice. Cells were
washed and resuspended in RPMI medium with 2%
fetal bovine serum. Populations of Lin−/CD45−/Sca-1+
(VSELs) and Lin−/CD45+/Sca-1+ (HSCs) were sorted
with a Moflo XDP cell sorter (Beckman Coulter).
Isolation of human VSELs
Clinical-grade UCB research units were shipped from
Cleveland Cord Blood Center. Total nucleated cells
(TNCs) were isolated by hypotonic lysing of red blood
cells (RBCs) employing BD PharmLyse lysing buffer (×2)
for 10 minutes at room temperature. After a washing
step, magnetic labeling of TNCs for the depletion of mature
hematopoietic lineage-positive cells (Lineage Cell Depletion
kit, Miltenyi Biotec) was performed. The population of
lineage-negative cells was isolated by using an autoMACS
separator (Miltenyi Biotec GMBH, Germany) and incu-
bated with antibodies: anti-CD2 (FITC, clone RPA-2.10),
anti-CD3 (FITC, clone UCHT1), anti-CD14 (FITC, clone
M5E2), anti-CD16 (FITC, clone 3G8), anti-CD19 (FITC,
clone HIB19), anti-CD24 (FITC, clone ML5), anti-CD56
(also known as N-CAM, FITC, clone NCAM16.2), anti-
CD66b (FITC, clone G10F5), anti-CD235a (FITC, clone
GA-R2 [HIR2]), anti-CD45 (PE or V450, clone HI30), and
anti-CD34 (APC or PE, clone 581) or anti-CD133/1 (APC
or PE, clone AC133). Cells were washed, resuspended,
and sorted using a MoFlo XDP cell sorter (Beckman
Coulter) to obtain populations enriched in VSELs
(Lin−/CD45−/CD133+ or Lin−/CD45−/CD34+) as well as
hematopoietic stem/progenitor cells (HSPCs, Lin−/CD45+/
CD133+ or Lin−/CD45+/CD34+).
In vivo BrdU labelling studies with murine VSELs
C57BL/6 mice (4 to 6 weeks old) were injected subcutane-
ously with human recombinant erythropoietin (Epogen, 25
U/day, 10 times, every third day) and injected intra-
peritoneally with BrdU solution (1 mg/animal, BD Phar-
mingen) every working day. Control mice were injected
with saline and BrdU solution. After 30 days, mice were
sacrificed, and a single-cell suspension was obtained and
stained for the VSEL phenotype as previously described.
After cell-surface staining of cells, the FITC BrdU Flow kit
(BD Pharmingen) staining protocol was used, which
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cells with DNase to expose incorporated BrdU, and staining
with anti-BrdU–FITC antibody. After washing, samples
were analyzed using a BD LSR II flow cytometer (BD Bio-
sciences). At least 106 events were acquired and analyzed
using BD FACSDiva software.Analysis of VSELs for the presence of erythroid markers
A single-cell suspension was obtained from 4- to 6-week-
old C57BL/6 mice and stained for the VSEL phenotype as
previously described. Additionally, cells ware stained for
markers characteristic of erythroid cells using antibodies:
anti-Ter119 (V450, clone TER-119) and anti-CD71 (FITC,
clone C2) for 30 minutes on ice. After washing, cells were
fixed and permeabilized with BD Cytofix/Cytoperm™
solution for 15 minutes on ice. The fluorescent DNA
intercalator 7AAD was added to samples to visualize
only flow cytometer events with DNA content. At least
2×106 nucleated events were acquired using a BD LSR
II flow cytometer (BD Biosciences, San Jose, CA).Detection of EpoR expression by FACS
Single-cell suspensions of mononuclear cells were obtained
from UCB research units and stained for the VSEL pheno-
type as previously described. Additionally, cells ware stained
for markers characteristic of erythroid cells using anti-
bodies: anti-CD235a (PE–Cy7, clone GA-R2 [HIR2]) and
anti-EpoR (APC, clone 38421) for 30 minutes on ice. After
washing, cells were fixed and permeabilized with BD
Cytofix/Cytoperm™ solution for 15 minutes on ice. 7AAD
was added to samples to visualize only events exhibiting
DNA content. At least 2×106 nucleated events were ac-
quired using a BD LSR II flow cytometer (BD Biosciences,
San Jose, CA).Immunohistochemical staining of FACS-sorted mBM-derived
VSELs
Lin−/CD45−/Sca-1+ murine VSELs as well as HSCs were
sorted, plated on 22-mm diameter plates coated with
poly-L-lysine (P9155, Sigma, MO, USA), and incubated
for 24 h. Subsequently, cells were fixed in 3.5% parafor-
maldehyde for 15 min, permeabilized by 0.1% Triton
X100, washed in PBS, and pre-blocked with 2.5% BSA
for 2.5 h at RT to avoid nonspecific binding of antibodies.
Immunocytochemistry for POU5F1 (clone 7 F9.2, mouse
monoclonal IgG1κ, Millipore, MA, USA), and EpoR (rabbit
polyclonal IgG, Abcam, Cambridge, MA, USA) proteins
was performed with appropriate secondary Alexa Fluor 488
goat anti-mouse IgG and Alexa Fluor 594 goat anti-rabbit
IgG antibodies. Nuclei were stained with DAPI (Invitrogen)
for 20 min at 37°C. All images were captured with an
Olympus FV1000 confocal microscope.Detection of EpoR expression by real-time quantitative
PCR (RQ-PCR)
Total RNA from FACS-sorted or cultured cells was iso-
lated using the RNeasy Mini kit (Qiagen Inc, Valencia, CA,
USA), with removal of genomic DNA using the DNA-free™
kit (Life Technologies, Grand Island, NY, USA). cDNA was
prepared with Taqman Reverse Transcription Reagents
(Applied Biosystems, Grand Island, NY, USA ), according
to the manufacturer’s instructions. Quantitative assessment
of mRNA levels of target genes was performed by RQ-PCR
using an ABI Prism 7500 sequence detection system
(Applied Biosystems). The cDNA templates from each
cell were amplified using SYBR Green PCR master mix
(Applied Biosystems), and specific primers (mEPO R:
forward, 5′-cattctggtcctcatctcgctg-3′, reverse, 5′-tgaa
gagaccctcaaactcgct-3′; hEPO R: forward, 5′-ccatgga
cactgtgccctg-3′, reverse, 5′- ccatcggataagccccctt-3′)
were designed with Primer Express software (Applied
Biosystems). The threshold cycle (Ct), the cycle num-
ber at which the fluorescence of the amplified gene
reached a fixed threshold, was subsequently deter-
mined, and the relative quantification of the expression
level of target genes was performed with the 2–ΔΔCt
method.
Conventional RT-PCR
Total RNA from various cells was isolated using the
RNeasy Mini kit (Qiagen Inc.), including treatment with
DNase I (Qiagen Inc.). The mRNA (200 ng) was reverse-
transcribed with Taqman Reverse Transcription Reagents
(Applied Biosystems) according to the manufacturer’s
instructions. The resulting cDNA fragments were ampli-
fied using Amplitaq Gold at 1 cycle of 8 min at 95°C,
2 cycles of 2 min at 95°C, 1 min at 60°C, 1 min at 72°C,
and subsequently by 37 cycles of 30 s at 95°C, 1 min at
60°C, 1 min at 72°C, and 1 cycle of 10 min at 72°C by




primers were designed using the NCBI/Primer-Blast
program, as at least one primer included an exon–intron
boundary.
Chemotaxis assay
Chemotaxis assays were performed in a modified Boy-
den’s chamber with 8-μm pore polycarbonate membrane
inserts (Costar Transwell; Corning Costar, Lowell, MA,
USA) as described previously. In brief, cells detached
with 0.25% trypsin were seeded into the upper chamber
of an insert at a density of 6 × 104 in 100 μl. The lower
chamber was filled with pre-warmed culture medium
containing test reagents. Medium supplemented with
0.5% BSA was used as a negative control. After 24 hours,
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The cells that had not migrated were scraped off with
cotton swap from the upper membrane, and the cells that
had transmigrated to the lower side of the membrane were
fixed and stained with HEMA 3 (protocol, Fisher Scientific,
Pittsburgh, PA) and counted on the lower side of the mem-
brane using an inverted microscope.
Cell adhesion assay
P19 murine teratocarcinoma cells were made quiescent
by incubation for 3 h at 37°C in αMEM medium supple-
mented with 0.5% BSA. The cells were then stimulated
with EpO 0.1, 1, and 100 U/ml for 5 min at 37°C, then
added to plates treated with fibronectin (10 μg/ml) and
incubated for 5 min at 37°C. After the non-adherent
cells had been discarded, cells that adhered to the stro-
mal cells were stained and counted under an inverted
fluorescence microscope.
Signaling studies
Human and murine teratocarcinoma or ovarian cancer
cells were kept overnight in medium containing low
levels of bovine serum albumin (BSA, 0.5%) to render
the cells quiescent. After the cells were stimulated with
EpO (1 or 100 U/ml for the P19 cell line; 0.5 or 10 U/ml
for the NTERA2 cell line; 50, 100, or 150 U/ml for the
A2780 cell line) for 5 min, cells were lysed for 20 min
on ice in RIPA lysis buffer containing protease and phos-
phatase inhibitors (Santa Cruz Biotech, Santa Cruz, CA).
The extracted proteins were separated on a 4–12% SDS-
PAGE gel and transferred to a PVDF membrane. The
phosphorylation of the p44/42 mitogen-activated kinase
(phospho-p44/42 MAPK) was detected by phospho-
specific p44/42 MAPK mouse and rabbit polyclonal
antibodies (Cell Signaling, Danvers, MA, USA) with
HRP-conjugated goat anti-mouse and anti-rabbit sec-
ondary antibodies (Santa Cruz Biotech). Equal loading
of protein in all the lanes was evaluated by stripping the
blots and reprobing with anti-p42/44 MAPK monoclonal
antibody (clone no. 9102, Cell Signaling). The membranes
were developed with an enhanced chemiluminescence
(ECL) reagent (Amersham Life Sciences, Arlington Heights,
IL), dried, and subsequently exposed to film (Hyperfilm,
Amersham Life Sciences).
Statistical analysis
All results were presented as mean ± SD. Statistical ana-
lysis of the data was performed using Student’s t-test for
unpaired samples, with p < 0.05 considered significant.
Results
Effect of EpO on proliferation of VSELs in murine BM
As previously described, VSELs are quiescent cells due to
epigenetic changes in certain paternally imprinted genes[24]. Since the first hematopoietic cells that emerge during
embryogenesis in yolk sac blood islands are primitive eryth-
roid cells, we became interested in whether prolonged ad-
ministration of EpO induces proliferation of these cells. To
address this question, normal 6-week-old animals were
injected s.c. with human recombinant EpO (25 U/day, 10
times, every third day) along with BrdU or saline (control
animals). Ten days later, animals were sacrificed, and we
analyzed the number of VSELs and HSCs in the cell cycle
according to BrdU incorporation as detected by FACS
(Figure 1 panel A). We observed that the number of BrdU
VSELs in mice injected with BrdU increased from ~ 2%
to ~20% compared with control saline-injected mice.
Importantly, to exclude potential contamination of
VSELs by the more differentiated erythroid progenitors,
we analyzed murine BM-purified VSELs for expression
of the erythroid cell markers Ter119 and CD71, and, as
shown in Figure 1 panel B, murine BM VSELs do not
express those antigens.
Murine and human VSELs express EpoR
To exclude the possibility that EpoR has an indirect effect
on VSEL expansion via accessory cells, we performed RT-
PCR analysis of EpoR expression on FACS-purified murine
and human VSELs and found that these cells express
mRNAs for this receptor (Figure 2 panel A). Subsequently,
we confirmed expression of EpoR on murine BM-purified
VSELs by immunofluorescence staining (Figure 2 panel B).
EpoR was also detected by FACS on ~15% of human
CD34+ and CD133+ VSELs purified from human UCB
(Figure 2 panel C).
Functional EpoR is expressed by murine and human
germline-derived cell lines
Based on evidence that several cancer cell lines [11,25-27],
including ovarian cancer cells [22,23,28,29], express EpoR,
we became interested in whether functional EpoR is
expressed by murine and human germline-derived cell
lines. Figure 3 shows the results of our studies performed
on the P19 murine teratocarcinoma cell line (panel A), the
NTERA2 human teratocarcinoma cell line (panel B), and
the A2780 human ovarian cancer cell line (panel C).
Figure 3 panel A shows that murine teratocarcinoma
cells express EpoR mRNA (a) and that this receptor is
functional, as demonstrated by chemotaxis assay (b), ad-
hesion assay (c), and direct signaling studies (d). Simi-
larly, as shown in Figure 3 panel B, NTERA2 human
teratocarcinoma cells express EpoR mRNA (a), EpoR is
detectable by FACS on these cells (b), its functionality
demonstrated by adhesion assay,(c) and direct signaling
studies (d). Finally, in addition to our teratocarcinoma
studies, which for the first time demonstrated EpoR ex-
pression by these cells, we also confirmed (Figure 3




Figure 1 Erythropoietin induces proliferation of quiescent BM VSELs. Panel A. BrdU incorporation into VSELs after EPO treatment. (a) The
percentage of VSELs that incorporated BrdU into newly synthesized DNA. After treatment with 10 doses of EPO at 25 U/dose, ~20% of VSELs are
BrdU+, in contrast to the control group (~2% of VSELs are BrdU+). (b) Incorporation of BrdU was measured by FACS. Representative FACS analysis
of six experiments is shown. Panel B. Analysis of VSELs for the presence of erythroid markers. Cells were fixed and stained with 7AAD to show
only events exhibiting DNA content, gate P1 (not shown). Gate P2 includes small, agranular cells. Gate P3 includes Sca-1+/Lin− cells, which are
visualized on the next dot plot as CD45-negative cells (VSELs) and CD45-positive cells (HSPCs). Erythroblast markers CD 71 and Ter-119 are not
expressed on VSELs (right, lower panel) in contrast to control cells, where some of the cells express CD71 and Ter-119 among the population
from the P2 gate (left, lower panel). One representative dot plot analysis out of three is shown.
Suszynska et al. Journal of Ovarian Research 2014, 7:66 Page 5 of 11
http://www.ovarianresearch.com/content/7/1/66expresses EpoR mRNA (a) and that this receptor is func-
tional according to chemotaxis assay (b) and direct cell
signaling studies (c).
Discussion
Our current understanding of stem cells in adult tissues
suffers somewhat from the lack of a broader view of thestem cell compartment, which is a continuum between
early stages of development and adult postnatal tissues.
The recent hot debate on the existence in BM of early-
development stem cells, such as spore-like stem cells,
multipotent adult stem cells (MASCs) [30], multilineage-
differentiating, stress-enduring (Muse) cells [31-33],
multipotent adult progenitor cells (MAPCs) [34,35],
AB
C
Figure 2 EpoR is expressed by murine and human VSELs. Panel A. RQ-PCR results for EpoR expression by purified murine (left panel) and
human (right panel) VSELs, HSCs, and MNCs. Combined data from three independent experiments are shown. Panel B. Immunostaining of
EpoR and Oct4 protein in purified murine VSELs (left panel) and HSCs (right panel). The images were acquired using an Olympus FV1000 confocal
microscope. A representative staining is shown. The experiment was performed on three independent cell sorts. Panel C. Detection of EpoR
expression by FACS among hCB-derived VSELs. The left panel presents the percentages of CD34+ and CD133+ VSELs that express EpoR. The level
of expression of EpoR on UCB-derived VSELs is ~20% for the population of Lin−/CD45−/CD34+ VSELs and ~15% for the population of Lin−/CD45−/CD133+
VSELs. The right panel shows one representative set of results out of ten FACS analyses.











Figure 3 (See legend on next page.)
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Figure 3 Functional EpoR is expressed on murine and human germline-derived immortalized cell lines. Panel A. (a) RT-PCR analysis of
EpoR expression in the P19 murine teratocarcinoma cell line. Upper panel, RQ-PCR data, lower panel, SDS-PAGE gel of RT-PCR amplicon. The
experiment was performed twice with similar results. (b). The effect of erythropoietin (0–100 U/ml) on adhesion of P19 cells to fibronectin.
Combined data from three independent experiments are shown. (c). The effect of erythropoietin (0–100 U/ml) on the chemoattraction of P19
cells across Transwell membranes covered with gelatin. Combined data from three independent experiments are shown. (d). Phosphorylation of
AKT and p42/44 MAPK in P19 cells. A representative blot is shown. Panel B. (a) RT-PCR analysis of EpoR expression in the NTERA2 human teratocarcinoma
cell line. Upper panel, RQ-PCR data; lower panel, SDS-PAGE gel of RT-PCR amplicon. Experiment was performed twice with similar results. (b). Expression of
EpoR on the NTERA2 cell line as measured by FACS. One representative histogram out of three experiments is shown. (c). Effect of erythropoietin (0–10 U/
ml) on adhesion of NTERA2 cells to fibronectin. Combined data from three independent experiments are shown. (d). Phosphorylation of AKT and p42/44
MAPK in NTERA2 cells. One representative blot out of two is shown. Panel C. (a) RT-PCR analysis of EpoR expression in the A2780 human ovarian cancer
cell line (lane 1). Lane 2, positive control (NTERA2 teratocarcinoma cell line). Lane 3, negative control (H2O instead of cDNA). The experiment was repeated
twice with similar results. (b). Effect of erythropoietin on chemoattraction of the A2780 ovarian cancer cell line across Transwell membranes. Combined
data from two independent experiments are shown. (c). Phosphorylation of p42/44 MAPK in the A2780 human ovarian cancer cell line stimulated by
erythropoietin. A representative blot is shown.
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cells [36], multipotent progenitor cells (MPCs) [30,37], and
very small embryonic-like stem cells (VSELs) [12-14,38]
with broader specification, resulted from the implicit chal-
lenge of these cells to the accepted hierarchy within the
stem cell compartment in adult tissues.
We have proposed that VSELs initially identified by us
[12,13,38] and confirmed by others [39-43] in murine
and human adult tissues are a link between early stages
of development and the compartment of adult stem cells
that reside in adult tissues. The epigenetic mechanism
identified in VSELs, which changes expression of certain
genes involved in insulin/insulin-like growth factor sig-
naling (IIS), keeps these cells in a highly quiescent state
in adult tissues [44-47]. However, we have demonstrated
that both murine and human VSELs may be specified
into the hematopoietic lineage. This finding was indir-
ectly corroborated by a recent report that the most
primitive HSCs in murine BM, corresponding to long-
term repopulating hematopoietic stem cells (LT-HSCs),
like VSELs, are kept quiescent by changes in certain
paternally imprinted genes involved in IIS [24,47]. In
addition, in an old report [17,48] small murine BM-
derived cells that share many characteristics with VSELs
have been demonstrated to be a population of LT-HSCs.
The existence in BM of developmentally primitive
stem cells with broader specification challenged the ac-
cepted hierarchy within the stem cell compartment in
murine BM and the developmental position in this hier-
archy of HSCs. Evidence has accumulated that HSCs can
become specified from a population of migrating prim-
ordial germ cells (PGCs) during embryogenesis [3-5]. In
support of this intriguing possibility, HSCs and PGCs
are highly migratory cells, and specification of the first
primitive HSCs in yolk sac blood islands as well as the
origin of definitive HSCs in the aorta–gonado–mesoneph-
ros (AGM) region are chronologically and anatomically
correlated with the developmental migration of PGCs in
extra- and intra-embryonic tissues [7]. Moreover, murineVSELs express several markers, such as Stella, Prdm14,
Fragilis, Blimp1, Nanos3, and Dnd1, that are shared with
migratory primordial germ cells PGCs [18,19]. Based on
these data, we have postulated a potential developmental
link between PGCs, VSELs, and HSCs [3,5,19], and, as re-
ported here in this study, the presence of EpoR on VSELs
purified from murine BM and human UCB lends further
support to this hypothesis.
We are aware that expression of EpoR (detected by
FACS) on human VSELs was low (~15%). This result,
however, depends on the affinity of antibodies against
EpoR as well as the number of copies of the receptor on
the cell surface. Moreover, we have demonstrated that
VSELs residing in adult BM are somewhat heteroge-
neous, being most likely (more or less) pre-committed
to various lineages [17,39-43,49]. We cannot exclude the
possibility that the cells that highly express EpoR as
detected by FACS staining are committed to HSCs. On
the other hand, as we have demonstrated, VSELs do not
express classical erythroid lineage markers such as Terr119
and CD71, and if this hematopoietic pre-commitment
occurs in BM-residing VSELs, it occurs at the level of
LT- HSCs.
In further support of a link between hematopoiesis
and the germline, it has been demonstrated that PGCs iso-
lated from murine embryos are able to grow hematopoietic
colonies in vitro [3]. Furthermore, the presence of early-
development stem cells with germline markers in BM that
are able to differentiate along the germline lineage has
already been demonstrated by several investigators. For ex-
ample, murine BM SSEA-1+ cells stimulated by bone mor-
phogenic factor 4 may differentiate Oct-4+Stella+Mvh+ cells
into gamete precursors [50]. Similarly, a population of Oct-
4+Mvh+Dazl+Stella+ cells present in murine BM has been
reported to affect the recurrence of oogenesis in mice steril-
ized by chemotherapy [51,52], and Oct-4+Mvh+Stella+ cells
isolated as Stra8–GFP cells from BM of Stra8–GFP trans-
genic mice express several molecular markers of spermato-
gonial stem cells and spermatogonia [6]. Furthermore,
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to give rise to functional sperm after injection into testes
[53]. In addition to BM, stem cells with germline potential
have also been isolated from newborn mouse skin and por-
cine skin as well as porcine adipose tissue [54].
The identification of early-development stem cells in
adult tissues raises several questions, such as: i) Are
these cells functional and do they play a role in tissue/
organ rejuvenation? ii) Are they involved in regulating
life span of the individual? iii) Are they involved in re-
generation of damaged tissues? iv) If regulatory mecha-
nisms fail, could these cells give rise to malignancies?
To address this last question, the concept that adult
tissues contain developmentally primitive cells with em-
bryonic features that can lead to tumors is, surprisingly,
not so novel. During the 19th and early 20th centuries,
it was proposed that cancer may develop in populations
of cells that are left in a dormant state in developing
organs during embryogenesis. This so-called “embryonic
rest hypothesis of cancer origin” was proposed by Virchow
(1855), Durante (1874), and Conheim (1875) [55-57].
According to these pathologists, adult tissues contain em-
bryonic remnants that normally lie dormant but that can
be activated to become cancerous. In agreement with these
theories, Wright (1910) proposed a germinal cell origin of
nephroblastoma, and Beard (1911) proposed that tumors
arise from displaced and activated trophoblasts or germ
cells [58,59]. However, the putative cells responsible for
these effects were at that time neither clearly identified
nor purified from adult tissues. As mentioned above, we
propose that mutated VSELs could be the missing link in
this hypothesis by being the origin of these malignancies.
There are several pieces of evidence supporting the
embryonic rest hypothesis of cancer development and
the potential involvement of VSELs. First, there is the
existence of classical germline tumors seen in patients
with seminomas, ovarian tumors, yolk sac tumors, medi-
astinal or brain germ cell tumors, teratomas, and terato-
carcinomas [60,61]. Second, several types of cancer cells
express cancer testis (C/T) antigens (~40 identified),
which are encoded by genes that are normally expressed
only in the human germline but are also often expressed
unexpectedly in various non-gonadal tumor types (e.g.,
gastric, lung, liver, and bladder carcinomas) [62,63].
Third, in several types of malignancies, embryonic
markers, such as chorionic gonadotropin (hCG) and/or
carcinoembryonic antigen (CEA), are detected in pa-
tient plasma [64]. Finally, it is known that several solid
tumors (e.g., gastric, lung, bladder, and oral mucosa
carcinomas as well as germinal tumors) express, like
VSELs, the embryonic/germline transcription factor
Oct-4 [65,66]. However, we are aware that more stud-
ies are needed to shed light on the potential role of
VSELs in tumorigenesis.In conclusion, we postulate that some support for the
embryonic rest hypothesis of cancer development is lent
by described by us herein presence of EpoR in both
VSELs and germline-derived cell lines. On the other
hand, since EpoR has been described in established cell
lines of several malignancies [8,11,22,23,25], though it
may be barely detectable on cells isolated from primary
tumors [67,68], we envision that it could be a novel
marker of cancer stem cells, for example, in gonadal
malignancies (e.g., ovarian cancer stem cells). This, how-
ever, requires further study. Finally, since it is known
that EPO signals in erythroid cells via EpoR-EpoR homo-
dimers and in nonerythroid cells may signal via EpoR-
CD131 heterodimers [69], thus while this paper was in
review we evaluated by FACS expression of CD131 on
human germ-line derived cells (VSELs, NTERA2, Ovar-
ian Cancer) and did not find expression of CD131 (not
shown).
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